Helus Pharma's 4Q26 HLP003 Phase 3 readout is the key near-term catalyst. Prior Phase 2 data showed a 23-point MADRS reduction and 71% remission at 12 months in adjunctive MDD, with a differentiated i

Helus Pharma buy rating tied to upcoming HLP003 Phase 3 readout catalyst.